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doi:10.1016/j.jtcvs.2004.02.02292 The Journal of Thoracic and CardiovObjective: Cardiopulmonary bypass induces a rise in cytokines released by activated
monocytes. The apolipoprotein E and the tumor necrosis factor  polymorphisms
are risk factors for atherosclerosis. The aim of the study was to investigate whether
the genetic variants of apolipoprotein E (APOE*E4) and tumor necrosis factor 
(TNFB*A329G) affect cytokine release after cardiopulmonary bypass.
Methods: Thirty-eight patients underwent standard coronary artery bypass grafting
procedures. Genotyping for APOE*E4 and TNFB*A329G was performed. Concen-
trations of interleukin 8 and tumor necrosis factor  were measured for 48 hours
after surgery. Clinical data were collected prospectively.
Results: Fourteen patients (37%) carried the combination non-APOE*E4/wild-type
TNFB*A329, 12 patients (32%) showed non-APOE*E4/TNFB*A329G, 9 patients
(24%) had APOE*E4/TNFB*A329G, and 3 patients (7%) had APOE*E4/wild-type
TNFB*A329. Total amount of tumor necrosis factor  was significantly higher in
patients carrying the combination APOE*E4/TNFB*A329 than in those carrying
non-APOE*E4/wild-type TNFB*A329 (P  .0001). Clinical data were similar
except for intubation time and amount of transfusion, which were significantly
increased in patients with genetic polymorphisms (P  .022, P  .033).
Conclusion: Presence of TNFB*A329G polymorphism in addition to APOE*E4
variant is associated with significantly higher releases of interleukin 8 and tumor
necrosis factor , prolonged intubation, and increased transfusion relative to patients
without genetic variants. Preoperative determination of APOE/TNFB genotypes in
patients undergoing coronary artery bypass grafting may lead to additional periop-
erative measures to ameliorate systemic inflammatory response.
Coronary artery disease (CAD) has a significant heritable element,falling into the category of a complex multigenetic disease.1 Avariety of candidate genes have been investigated as predisposingfactors for CAD, including those involved in lipid metabolism.1
The importance of apolipoprotein E (ApoE)–mediated increases in cholesterol
level in the severity of atherosclerosis has been controversial.2,3 However, several
studies have identified a relationship between the ApoE genotype and atheroscle-
rosis. These studies indicate that the allele for the 4 variant of ApoE, APOE*E4,
contributes to the development of atherosclerosis and is a major factor responsible
4,5for predisposition to this disease.
ascular Surgery ● July 2004
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PThe APOE gene is polymorphic, resulting in three com-
mon alleles (*E2, *E3, and *E4) and six different genotypes
APOE*E2/*E2, APOE*E3/*E2, APOE*E4/*E2, APOE*E3/
*E3, and APOE*E3/*E4, APOE*E4/*E4).2 The APOE*E4
allele is associated with high serum total and low-density
lipoprotein cholesterol concentrations,6 which in turn are
well-established risk factors for CAD.7
Recently, a number of genes involved in the inflamma-
tory response have also aroused interest.2 The atheroscle-
rotic plaque undergoes many changes consistent with a
chronic inflammatory process.8 The proinflammatory cyto-
kine tumor necrosis factor (TNF)  has been localized in
atheromatous plaques and may contribute to the progression
of atheroma by augmenting the inflammatory response.9
TNF- secretion shows a high degree of interindividual
variability, which is at least in part genetically deter-
mined.10 A number of TNF- and - gene polymorphisms
are known with the theoretical potential to affect either
cytokine function or secretion.11-13 Although as yet no
functional studies of these polymorphisms have been per-
formed, they have been investigated in inflammatory con-
ditions 14 Because of the evidence implicating ApoE and
TNF- and - in the pathogenesis of CAD, we have inves-
tigated whether polymorphisms in the APOE and TNFB
genes are also related to the severity of proinflammatory
cytokine release in patients undergoing cardiopulmonary
bypass (CPB) procedures.
Patients and Methods
Patient Groups
During the 18-month period from February 2000 to August 2001,
a total of 38 patients undergoing coronary artery bypass grafting
(CABG) were selected for the study. Informed consent was ob-
tained from each patient according to the protocol of the ethics
committee of the University Hospital Zu¨rich. Patients with known
infection, known neoplasm, previous CABG, or a preoperatively
inserted intra-aortic-balloon pump were excluded from the study.
Operative Techniques
CPB was performed with a Sto¨ckert roller pump system (Sto¨ckert
Instrumente GmbH, Munich, Germany) and a Shiley-Dideco Max-
ima hollow-fiber oxygenator (Dideco, Mirandola, Italy). Cold
blood cardioplegic solution with an initial dose of 15 mL/kg was
applied for myocardial protection. Repeated infusions of 300 mL
were given every 15 minutes or earlier if electrical activity oc-
curred. Before aortic declamping, 500 mL warm blood cardiople-
gic solution (hot shot) was administered at 37°C for 2 minutes at
a pressure of 50 mm Hg. Rewarming to a rectal temperature
greater than 34°C was achieved with a heat-exchange oxygenator,
warming blanket, and heated, humidified gases.
Blood Sampling and Analysis
For each patient peripheral venous blood samples were obtained
through a central venous catheter at 10 different time points. At the
first time an additional tube of ethylenediaminetetraacetic acid–
The Journal of Thoracanticoagulated blood was drawn for genotyping. The first sample
was taken before anesthesia, the second half an hour after reopen-
ing of coronary circulation (declamping of aorta), the third 1 hour
after reopening of the coronary circulation, the fourth 2 hours after
reopening of the coronary circulation, the fifth 4 hours after re-
opening of coronary circulation, the sixth 8 hours after reopening
of the coronary circulation, the seventh 16 hours after reopening of
the coronary circulation, the eighth 24 hours after reopening of the
coronary circulation, the ninth 32 hours after reopening of the
coronary circulation, and the tenth 48 hours after reopening of the
coronary circulation.
After centrifugation, serum or plasma samples were frozen
immediately at 80°C until analysis. The following parameters
were measured off-line for all samples: inflammation parameters,
namely TNF-, interleukin (IL) 8, and c-reactive protein. Geno-
typing was performed for the following loci: APOE4 and TNFB.
Concentrations of TNF  and IL-8 in the serum were deter-
mined by automated enzyme chemiluminescence immunoassay on
an Immulite I system (Diagnostics Product Corporation, Los An-
geles, Calif, and Buehlmann Laboratories AG, Allschwil, Switzer-
land). For genotyping, genomic DNA was extracted from 200 L
of ethylenediaminetetraacetic acid–anticoagulated blood with the
MagNA Pure LC (Roche Diagnostics, Rotkreuz, Switzerland) and
real-time polymerase chain reaction was performed on a LightCy-
cler (Roche Diagnostics) according to the method of Aslanidis and
coworkers15 with primers and hybridization probes synthesized by
TIB MolBiol (Berlin, Germany).
Clinical Variables
For each patient, medical history and demographic data as well as
the postoperative course were collected prospectively. Data in-
cluded length of intensive care unit stay, length of hospital stay,
and occurrence of myocardial infarction, bleeding, arrhythmia, or
other complications, such as infection necessitating antibiotic
treatment.
Statistical Methods
The Fisher exact test and the Student t test with mean and SDs
were used for comparison of ratios and means for normally dis-
tributed data. The Mann-Whitney test was used where applicable.
All measurements between the various groups were controlled for
all time points by repeated-measures analysis of variance with
Bonferroni corrections.
Results
Of the 38 patients enrolled, 14 patients (37%) carried the
combination non-APOE*E4/wild-type TNFB*A329, 12 pa-
tients (32%) showed a non-APOE*E4/TNFB*A329G geno-
type (10 heterozygous, 2 homozygous), 9 patients (24%)
had the combination of APOE*E4/TNFB*A329G (8 het-
erozygous, 1 homozygous) and 3 patients (7%) had
APOE*E4/wild-type TNFB*A329. For the sake of under-
standing, we first focused on the two groups of patients with
wild-type TNFB*A329 versus the TNFB*A329G carriers
regardless of the APOE status. Second, we compared the
patients with both polymorphisms (APOE*E4/TNFB*A329G)
with the patients with no polymorphism (non-APOE*E4/
ic and Cardiovascular Surgery ● Volume 128, Number 1 93
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profile (age, sex, diagnosis, risk factors) between the wild-
type TNFB*A329 versus the TNFB*A329G carrier group
demonstrated no statistical difference. Furthermore, the in-
traoperative management between the two groups of pa-
tients conferred comparability, because no statistically sig-
nificant differences could be demonstrated (Table 1).
TNF- and IL-8 plasma levels before the operation were
comparable in all patients. However, in TNFB*A329G het-
erozygous or homozygous carriers significantly higher
amounts of TNF- were found at 1 hour (P .025), 2 hours
(P  .043), and 24 hours (P  .011) after reopening of the
coronary circulation. Highest levels of circulation TNF-
were found 4 hours after reopening of the coronary circu-
lation. The total output of TNF- (measured as areas under
the curve) was significantly higher in patients carrying the
TNFB*A329G genetic variant than in the wild-type carriers,
with 101.9  56.1 pg/mL and 77.7  29.6 pg/mL, respec-
tively (P  .01; Figure 1).
Similar results were found for IL-8, with higher levels of
IL-8 demonstrated in the TNFB*A329G heterozygous and
homozygous group compared with the TNFB wild-type
group, with statistical significance at 4 hours (P  .041), 8
hours (P  .032), and 16 hours (P  .049) after reopening
of the coronary circulation. The total apparent cytokine
output of IL-8 (measured as areas under the curve) was
higher in patients either heterozygous or homozygous for
the TNFB*A329G genetic variant than in those homozygous
for the TNFB wild-type allele, with 314.0  107.4 pg/mL
versus 127.1  76.0 pg/mL, respectively (P  .01; Figure
2).
With respect to patients with the combination of both
polymorphisms, in APOE*E4/TNFB*A329G heterozygous
and homozygous carriers significantly higher levels of
TNF- than in patients with no polymorphisms at all (non-
APOE*E4/TNFB*A329) were found at 0.5 hours (P 
TABLE 1. Demographics, intraoperative data, and clinical
heterozygous or homozygous for the TNFB*A329G polymor
Wild type
APOE*E4 (No.) 3
Age (y, mean  SD) 66.9
Gender (female/male) 0:1
Ejection fraction (%, mean  SD) 62
Bypass time (min, mean  SD) 88
Crossclamp time (min, mean  SD) 53
Intubation (min, mean  SD) 773
Transfusions (U, mean  SD) 0.8
Intensive care unit stay (d, mean  SD) 1.5
Infections (No.) 1
Atrial fibrillation (No.) 4
Hospital stay (d, mean  SD) 10.5
NS, Not significant. Statistical significance was defined as P  .05..007), 1 hour (P .0006), 4 hours (P .042), and 24 hours
94 The Journal of Thoracic and Cardiovascular Surgery ● July 2(P  .003) after reopening of the coronary circulation. The
highest levels of circulating TNF- were found after 4 hours
in both groups; mean level was statistically significantly
higher in APOE*E4/TNFB*A329G heterozygous and ho-
mozygous carriers, with 13.2 6.3 pg/mL versus 7.9 3.1
pg/mL in the non-APOE*E4/TNFB*A329 wild-type carrier
group (P  .0002). The total apparent cytokine output of
TNF- (measured as area under the curve) was significantly
higher in patients carrying both mutations than in the non-
APOE*E4/TNFB*A329G heterozygous and homozygous
carrier group, with 132.5  63.0 pg/mL versus 79.0  30.9
pg/mL, respectively (P  .0001; Figure 3).
Clinical data were similar in all groups except for the
duration of intubation and the amount of transfusions. Both
were significantly increased in patients with two genetic
variants versus none (Table 2).
Discussion
This study showed that the presence of the TNFB*A329G
allele is linked to an increase of cytokine release in patients
after CPB. Interestingly, the combination of APOE*E4 and
TNFB*A329G genetic variants was associated with a further
increase in TNF- plasma level.
CPB is known to cause an inflammatory response,
mainly as a result of the contact of blood with artificial
surfaces of the bypass circuit and the reperfusion phenom-
enon. This inflammatory reaction includes activation of the
humoral and cellular immune system, which leads to in-
creased cytokine release. Recent studies demonstrate that
CABG without the use of CPB was associated with a
reduction of the inflammatory response combined with de-
creased postoperative morbidity and mortality.16,17 Whether
this inflammatory response is due solely to the use of CPB
is being debated. However, a genetic background may also
play a role in influencing cytokine plasma levels induced by
cardiac operations. Inbal and associates18 found an
ome for patients with wild-type TNFB and patients either
m
17) Polymorphism (n  21) P value
9 NS
62.5 8.3 NS
4:17 NS
62 11 NS
104 25 NS
57 10 NS
1427 841 .043
2.4 2.7 NS
2.4 1.8 NS
0 NS
1 NS
9 1.9 NSoutc
phis
(n 
5.3
7
10
15
10
234
0.9
0.7
3.3APOE*E4 allele frequency of 9.4% in young men with an
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repre
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Pacute myocardial infarction versus 5.3% in a control group.
In this study, patients with a APOE*E4 polymorphism had
a 9-fold increased estimated risk of development of an acute
myocardial infarction.
In addition, evidence exists suggesting that the genetic
variations of TNF locus are involved in determining sus-
ceptibility to inflammatory autoimmune diseases such as
rheumatoid arthritis and asthma.19 We therefore evaluated
whether the genotype APOE*E4 variant and the
TNFB*A329G allele are connected to the release of proin-
flammatory cytokines during CPB surgery. Our results sug-
gest that the APOE*E4 variant and the TNFB*A329G allele
may be important in the production or release of TNF- and
IL-8 at a molecular level.
In an isolated rat heart model of ischemia and reperfu-
sion injury the local production and release of TNF- leads
to significant depression of coronary flow as well as a
decreased myocardial contractility and an increase of crea-
20
Figure 1. TNF- at different time points for TNFB w
homozygous (TNF beta het or hom) carriers. Time point
of anesthesia. Data points represent mean; error bars
Figure 2. IL-8 at different time points for TNFB wil
homozygous (TNF beta het or hom) carriers. Time point
of anesthesia. Data points represent mean; error barstine kinase production, therefore APOE*E4 as well as
The Journal of ThoracTNFB*A329G polymorphism carriers might be at higher
risk for development of more severe myocardial dysfunc-
tion during CPB surgery. TNF- is believed to be a pivotal
proinflammatory cytokine in the pathogenesis of the sys-
temic inflammatory response syndrome. Recently it has
been shown that a genomic restriction fragment length
polymorphism within the TNF locus is correlated with
increased TNF- plasma levels and poor prognosis in sep-
sis.21 TNF- is also known to be a potent inducer of the
synthesis of secondary proinflammatory mediators such as
IL-8. IL-8 is a crucial cytokine known to attract and activate
neutrophils and is known to play a role in the pathophysi-
ology of the capillary leak syndrome.22
Interestingly, the combination of APOE*E4 variance and
the TNFB*A329G polymorphism lead to an additional in-
crease of TNF- relative to the patients with the
TNFB*A329G genetic variant alone. These results show
that the production or release of cytokines is not regulated
pe (TNF beta wt) and TNFB*A329G heterozygous or
x axis indicates sample taken immediately before start
sent SD.
e (TNF beta wt) and TNFB*A329G heterozygous or
x axis indicates sample taken immediately before start
sent SD.ild-ty
0 ond-typ
0 onby only one gene polymorphism but most likely is also due
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CSPto a linked process with other genetic variants. Newman and
colleagues23 hypothesized that patients with the APOE*E4
allele are predisposed toward coronary artery disease and
would be seen earlier for surgery.23 Whether the patients in
that study demonstrated the APOE*E4 polymorphism alone
or had additional genetic variances is unfortunately unknown.
In our patients who underwent elective CABG, no sig-
nificant differences could be demonstrated in the clinical
outcome except for the length of intubation and the amount
of blood transfusion, both of which were significantly
higher in patients with both genetic variants. However, it is
hard to prove a clear causal relationship between the eleva-
tion of cytokines and the clinical outcome. Whether the
increased cytokine release in patients with polymorphisms
is due to more transfusions given is debatable, but we
Figure 3. TNF- at different time points for non-APO
APOE*E4 and TNFB*A329G heterozygous or homozygo
indicates sample taken immediately before start of an
SD.
TABLE 2. Demographics, intraoperative data, and clinical o
patients with APOE*E4 and either heterozygous or homozy
Both pol
(n
Age (y, mean  SD) 65.8
Gender (female/male)
Ejection fraction (%) 63
Bypass time (min, mean  SD) 103
Crossclamp time (min, mean  SD) 60
Intensive care unit stay (d, mean  SD) 2.1
Intubation time (min, mean  SD) 1515
Transfusions (U, mean  SD) 3
Infections (No.)
Atrial fibrillation (No.)
Hospital stay (d, mean  SD) 9.1
NS, Not significant.believe that it is rather an aspect of inflammation. A patient
96 The Journal of Thoracic and Cardiovascular Surgery ● July 2population with more severe conditions would probably
have demonstrated more clinical relevance than what we
saw in our study. Turner and associates24 reported on a heart
transplantation cohort in which the combination of a low
IL-10 producer genotype *1082AA with the high TNF-
producer allele *308A was correlated with increased levels
of early heart transplant rejection.24
In conclusion, preoperative APOE4 and TNFB genotyp-
ing may be a useful tool in deciding whether patients with
genetically determined increased proinflammatory cytokine
production and release could benefit from avoiding CPB
now that off-pump CABG has evolved as a true alternative
to on-pump procedures. Furthermore, genotyping may be
used for selecting high-risk patients for intensive monitor-
ing and additional perioperative measures for the treatment
and TNFB wild-type carriers (nonE4/TNF-B wt) vs
rriers (E4/TNF-B het or hom). Time point 0 on x axis
sia. Data points represent mean; error bars represent
me for patients with non-APOE*E4 and wild-type TNFB and
for the TNFB*A329G polymorphism
hisms No polymorphisms
(n  9) P value
9 69 3.7 NS
0:14 NS
63 10 NS
89 17 NS
53 11 NS
4 1.5 0.8 NS
1 810 257 .022
7 0.79 0.9 .033
1 NS
1 NS
9 10.3 3.4 NSE*E4
us ca
estheutco
gous
ymorp
 14)
 8.
2:7
 10
 14
 8
 1.
 69
 2.
0
0
 1.of the increased systemic inflammatory response.
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